DAFTAR PUSTAKA

1. Erawati M, Andriany M. The prevalence and demographic risk factors for Latent Tuberculosis Infection (LTBI) among healthcare workers in Semarang, Indonesia. *J Multidiscip Healthc* .2020:13 :198
2. Ai JW, Ruan QL, Qi-Hui Liu HQ, et al. Updates on the risk factors for latent tuberculosis reactivation and their managements. *Emerging Microbes and Infections*. 2016 Nov 23; 5 : 1
3. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection:A re-estimation using mathematical modelling. *PLoS Med*. 2016 oct 25; 13(10): 2
4. Schablon A, Harling M, Diel R, Nienhaus A. Risk of latent TB infection in individuals employed in the healthcare sector in Germany: a multicenter prevalence study. *BMC Infect Dis*. 2010. 10: 10
5. Rafiza S, Rampal KG, Tahir A. Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia. *BMC Infect Dis*.2011.11: 19
6. Patona N, Borandb L, Benedictoc J, et al. Diagnosis and management of latent tuberculosis infection in Asia: Review of current status and challenges. *International Journal Infect Dis*. 2019 Jul 5 : 21–29
7. Zhang X, Jia H, Liu F, Pan L, Xing A, et al. Prevalence and risk factors for latent tuberculosis infection among health care workers in China: A Cross-Sectional Study. *PLoS ONE*. 2013 Jun 8(6): 1.

8. Irene L , Jose D. Dormancy antigens as biomarkers of latent tuberculosis infection.*EBioMedicine*. 2015 : 790–791
9. Hernández-Pando R, Jeyanathan M, G Mengistu G, et all .Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. *The Lancet*. 2000 Dec 23 ;356 : 2133
10. Akinshipe B, Yusuf E, Ehiaghe A, et al. Elevated high-sensitivity C reactive protein among apparently healthy adults with concomitant prediabetes and latent tuberculosis infection in Nigeria. *Int J Res Med Sci*. 2021 Feb;9(2):339-343
11. Ockene IS, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. *Clin Chem*. 2001 : 47:444-50.
12. Irving K, David S, Marina M. A unifying biologic explanation for "high-sensitivity" Creactive protein and "low-grade" inflammation. *Arthritis Care and Research*. 2010;62(4):442–6.
13. Pan L, Li G, Wan S,et al. The association between high-sensitivity C-reactive protein and blood pressure in Yi people. *BMC Public Health*. 2019;19:991
14. Mahajan A, Tabassum R, Chavali S. High-Sensitivity C-Reactive Protein Levels and Type 2 Diabetes in Urban North Indians. *J Clin Endocrinol Metab*. 2009; 94(6):2123
15. Dinh KM, Kaspersen KA, Mikkelsen S, et al. Low-grade inflammation is negatively associated with physical Health-Related Quality of Life in

healthy individuals: Results from The Danish Blood Donor Study (DBDS). *PLoS ONE*. 2019; 14(3): e0214468

16. Tomasik A W, Paczek B C ,Zielenkiewicz M et al . Inflammatory markers change with age, but do not fall beyond reported normal ranges. *Arch. Immunol. Ther*.2015 Aug 18.(64):249–251
17. Gaskins A J, Wilchesky M, Mumford S , et al. Endogenous reproductive hormones and C reactive protein across the menstrual cycle. *Am J Epidemiol*. 2012 Jul 12;175(5):423–431
18. Word Health Organization. Latent tuberculosis infection. Updated and consolidated guidelines for programmatic management. Geneva.2015
19. Ahmad S. Pathogenesis, Immunology and diagnosis of latent mycobacterium tuberculosis infection. *Clinical and Developmental Immunology*. 2010 Oct 28 : 1-2
20. Uyainah, Soeroto,Riyanto,et al.Tuberculosis : Tinjauan dan tatalaksana komphrensif terkini. Jakarta : *PIP Interna*; 2019 :161
21. Dutta N K,Petros C. ,Karakousis P C. Latent Tuberculosis infection: Myths, Models, and Molecular Mechanisms. *Microbiol Mol Biol Rev*. 2014 Sep; 78(3): 343
22. Rohini K , Srikumar P S, Saxena J, et al. Assessment of serum calcium, phosphorus, c-reactive protein and Procalcitonin in Tuberculosis patients. *Int J Res Public Health*. 2012 ; 4 (12):1871

23. Mack U, Migliori G.B , Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. *European Respiratory Journal*. 2008 Dec 12 . (33) : 956-7
24. LaVergne S, Umlauf A, McCutchan. A.impact of Latent tuberculosis infection on neurocognitive functioning and inflammation in HIV-Infected and uninfected south indians. *J Acquir Immune Defic Syndr*. 2020;84:430
25. Shiratori B, Saitoh H, Siddiqi U R,et al. Immunological Diagnosis of Active and Latent TB. Understanding Tuberculosis – Global Experiences and Innovative Approaches to the Diagnosis. 2014 May 31:357
26. Huaman M, Ticona E, Miranda G, et al. The relationship between Latent tuberculosis infection and acute myocardial infarction. *Clinical Infectious Diseases*. 2018 Aug 12 ;66(6):889–91
27. Huaman M, Henson D, Ticona E, et al. Tuberculosis and cardiovascular disease: linking the epidemics. Tropical Diseases, Travel Medicine and Vaccines. 2015; 1:10
28. Cavalcanti Y, Brelaz M. Role of TNF-Alpha, IFN-Gamma, and IL-10 in the development of pulmonary tuberculosis. *Hindawi Publishing Corporation Pulmonary Medicine*. 2012 Nov 5; 12 : 3
29. Sullivan ZA, Wong EB, Ndung'u T, et al. Latent and active tuberculosis infection increase immune activation in individuals Co-infected with HIV. *EBioMedicine*. 2015 : 339

30. Roberto Colangeli R, Gupta A, Vinhas SA, et a. Mycobacterium tuberculosis progresses through two phases of latent infection in humans. *Nature Communications*. 2020 ;11:4870
31. Carranza C, Sanchez P, Torres M. Diagnosis for latent tuberculosis infection: New Alternatives. *Front. Immunol*. 2020 Sept 10: 11
32. Lassale C, Batty GD, Steptoe A, et al. Association of 10-year C-reactive protein trajectories with markers of healthy aging: findings from the English Longitudinal. *Study of Ageing*. 2018 Feb 15 :3
33. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. *Clinical Observations, Interventions, and Theraupethic Trials*. 2005 Marc 15 ;105 (6) :2295
34. Shastri M D, Shukla S D , Chong W C. Role of oxidative stress in the pathology and management of human tuberculosis. *Oxidative Medicine and Cellular Longevity*. 2018 oct 11 : 2-3
35. Bourgonje MF, Bourgonje AR, Abdulle AE,et al.Systemic oxidative stress, aging and the risk of cardiovascular events in the general female population. *Front. Cardiovasc. Med*. 2021 ;8:9
36. Sproston NR, Ashworth JJ . Role of c-reactive protein at sites of inflammation and infection. *Front. Immunol*. 2018. (9);754 : 1-2
37. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. *Clin Chem*.2001;47:444-50

38. Pepys MB, Hirschfied GM. C-reactive protein. A critical update. *J Clin Invest*. 2003 Jun ;111:1805
39. Dinh KM, Kaspersen KA, Mikkelsen S, et al. Low-grade inflammation is negatively associated with physical Health-Related Quality of Life in healthy individuals: Results from The Danish Blood Donor Study (DBDS). *PLoS ONE*. 2019; 14(3): e0214468
40. Hod K, Dickman R, Sperber A, et al. Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome. . *Neurogastroenterol Motil* .2011; 23: 1105
41. Tang Y, Liang P, Chen J et al. The baseline levels and risk factors for high-sensitive C-reactive protein in Chinese healthy population. *Immunity & Ageing* .2018; 15(21):1
42. Khan DA, Ansari WM, Saleem, et al.Reference value for high-sensitivity c-reactive protein in the northern pakistani population. *Pak Armed Forces Med J* .2009; 59(4):420
43. Cartier A, Coˆte´ M, Lemieux I, et al. Sex differences in inflammatory markers: what is the contribution of visceral adiposity. *Am J Clin* Nutr.2009;89:1308